Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

Congress meeting · Dr. Chloé Xu

09 Aug 2026 · In person · Dr. Chloé Xu, Gustave Roussy · MSL Mei Tanaka · Vantrexa

ReviewedVeeva CRMENG-0112—

Capture insight from this engagement

Location: Gustave Roussy
Therapeutic area: Oncology
Country: France
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: MTMei TanakaMSL, Oncology (Japan)
Product: Vantrexa (vantrelimab)

Topics discussed

PD-L1 testing turnaround

Scientific content used

VOYAGE-1 pivotal data summary
PD-L1 testing pathway infographic

Questions raised

How should grade 2 infusion reactions be managed without steroids?
Is there subgroup data for patients with untreated brain metastases?

Notes

Congress meeting with oncology pharmacist at Gustave Roussy. Discussed pd-l1 testing turnaround.

Insights captured (1)

Capture insight

INS-0010High
PD-L1 testing turnaround
PD-L1 testing turnaround: request for data reported by oncology pharmacist (FR).
Action in progress

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 3
Depth of exchange: 3
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0112

Audit history (1)

All create, update and approval events for this record

Time	Action	User	Field	Change	Reason	Source
08 Sept 2026, 07:05 UTC	Update	FAFatima Al-Sayed	notes	— → Reviewed	—	UI